Wedgewood Partners’s Bristol-Myers Squibb BMY Stock Holding History

Wedgewood Partners’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-4,175	Closed	-$300K	–	38
2022 Q4	$300K	Sell	4,175 -1,250	-23%	-$94.3K	0.06%	36
2022 Q3	$385K	Sell	5,425 -500	-8%	-$36.3K	0.07%	33
2022 Q2	$456K	Sell	5,925 -1,000	-14%	-$76.2K	0.08%	33
2022 Q1	$505K	Buy	6,925 +2,250	+48%	+$151K	0.07%	32
2021 Q4	$291K	Sell	4,675 -625	-12%	-$36.7K	0.04%	36
2021 Q3	$313K	Sell	5,300 -325	-6%	-$21.4K	0.04%	36
2021 Q2	$375K	Sell	5,625 -70,210	-93%	-$4.58M	0.05%	36
2021 Q1	$4.79M	Sell	75,835 -338,222	-82%	-$21M	0.74%	23
2020 Q4	$25.7M	Sell	414,057 -25,262	-6%	-$1.55M	3.82%	15
2020 Q3	$26.5M	Buy	439,319 +65,538	+18%	+$3.94M	4.19%	12
2020 Q2	$22M	Buy	373,781 +114,601	+44%	+$6.85M	3.72%	12
2020 Q1	$14.4M	Sell	259,180 -132,262	-34%	-$8.08M	2.74%	16
2019 Q4	$25.1M	Buy	+391,442	New	+$22.4M	2.55%	17

Other funds holding BMY

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Wedgewood Partners's BMY Position: Q1 2023 in Review

Wedgewood Partners sold out of Bristol-Myers Squibb (BMY) in Q1 2023, closing a stake of 4,175 shares — an estimated $300K sold.

Wedgewood Partners first reported a position in BMY in Q4 2019 and held it in 13 quarters. The position peaked at $26.5M in Q3 2020. 2,540 funds tracked by Wall St. Rank hold BMY as of Q1 2023.

Wedgewood Partners reported no remaining Bristol-Myers Squibb position as of Q1 2023 after selling out during the quarter.
Wedgewood Partners sold 4,175 Bristol-Myers Squibb shares in Q1 2023, an estimated $300K.
Wedgewood Partners first reported a position in Bristol-Myers Squibb in Q4 2019 and held it in 13 quarters.
Wedgewood Partners's Bristol-Myers Squibb position peaked at $26.5M in Q3 2020.
2,540 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2023.

Based on Wedgewood Partners's 13F filing for Q1 2023, filed 15 May 2023.